VCM
RXRX icon

Voleon Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Voleon Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270K Buy
87,848
+60,255
+218% +$233K 0.01% 684
2025
Q4 		$113K Buy
+27,593
New +$137K ﹤0.01% 749

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voleon Capital Management's RXRX Position: Q1 2026 in Review

Voleon Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 218% in Q1 2026, buying an estimated $233K and bringing the position to 87,848 shares worth $270K. The position accounts for 0.01% of the portfolio, ranked #684.

Voleon Capital Management first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Voleon Capital Management held 87,848 shares of Recursion Pharmaceuticals worth $270K as of Q1 2026.
  • Voleon Capital Management bought 60,255 Recursion Pharmaceuticals shares in Q1 2026, an estimated $233K.
  • Recursion Pharmaceuticals made up 0.01% of Voleon Capital Management's portfolio in Q1 2026, its #684 holding.
  • Voleon Capital Management first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.